Boehringer Ingelheim and Eli Lilly's Jardiance, or empagliflozin, will undergo fast track review by the FDA as a medication to prevent hospitalization due to heart failure and also to lower the risk for all-cause mortality in adult patients with and without diabetes that have experienced a previous myocardial infarction.
Empagliflozin for heart failure fast-tracked by FDA
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.